Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer

JHOP - December 2017 Vol 7, No 4 - Breast Cancer

Arm morbidity is frequently observed after surgery for breast cancer, but can have a greater detrimental impact on younger women “given their long survivorship period, frequently active lifestyle, and the importance of body image,” said Anne Kuijer, PhD, a postdoctoral research fellow at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA. “These issues are of particular importance in these patients.”

Severe arm morbidity is less common than it once was with a movement toward sentinel lymph node biopsy (SLNB) and away from axillary lymph node dissection (ALND), which can cause extensive swelling in the arm due to surgery to remove lymph nodes (lymphedema). The rate of lymphedema is about 20% and the rate of shoulder impairment can be as high as 28% as late effects following axillary surgery. However, these problems have not been studied specifically in younger women.

To assess the incidence of arm morbidity associated with ALND and SLNB, Dr Kuijer and colleagues examined 10 years of reports (2006-2016) from 1302 women aged ≤40 years who were enrolled in the Young Women’s Breast Cancer Study. Fifty-five percent of the women had undergone an SLNB only and 41% had undergone ALND. In 4% of patients, no axillary surgery was performed.

The investigators examined the incidence of patient-reported arm swelling or decreased range of motion 1 year after diagnosis. Overall, 13% reported arm swelling and 40% reported decreased range of motion in the ipsilateral arm—the arm on the same side as the breast tumor—1 year after their breast cancer diagnosis.

Among the patients who were treated with breast-conserving surgery, the incidence of arm swelling 1 year after diagnosis was 6% in patients who underwent SLNB and 24% in those who received ALND. For patients who underwent unilateral or bilateral mastectomy, the incidence of arm swelling was 6% in the SLNB group and 23% in the ALND group.

Among the women who underwent breast-conserving surgery, the rate of decreased range of motion in the ipsilateral arm was 32% and 36% in patients who underwent SLNB or ALND, respectively. Among those who underwent unilateral or bilateral mastectomy with SLNB or ALND, these rates were 28% and 44%, respectively.

Certain patient factors were associated with greater risk of arm morbidity. For example, being overweight at the time of diagnosis increased the risk for arm swelling and decreased range of motion. In addition, women who described themselves as financially comfortable were less likely to develop arm swelling.

Dr Kuijer said that because the study included women who were treated at large cancer centers in the Northeast, and thus were likely to have a high socioeconomic status, the incidence of arm morbidity may be even higher in the general population.

The findings highlight the importance of de-escalating axillary treatment when appropriate in young patients with breast cancer, and illustrates that even conservative surgery has long-lasting effects. “Women should be encouraged to talk to their doctors about all of their options for surgery and the expected outcomes,” Dr Kuijer concluded.

Source:
Kuijer A, Dominici LS, Rosenberg SM, et al. Risk of arm morbidity after local therapy in young breast cancer survivors. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS5-03.

Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: